News

Beta Bionics to Announce Second Quarter 2025 Financial Results on July 29, 2025

IRVINE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2025 financial results after the financial markets close on Tuesday, July 29, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time).

07/02/2025

BBNX Stock May Gain From Abbott Deal to Advance iLet Integration

Beta Bionics collaborates with Abbott to integrate its iLet system with a dual sensor, aiming to simplify and enhance diabetes care.

06/23/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Beta Bionics, Inc. Common Stock (BBNX) a buy, sell, or hold?

Beta Bionics, Inc. Common Stock (BBNX) can sell. Click on Rating Page for detail.

What is Beta Bionics, Inc. Common Stock's stock price?

The price of Beta Bionics, Inc. Common Stock (BBNX) is 12.67 and it was updated on 2025-07-12 01:51:46.

Is Beta Bionics, Inc. Common Stock (BBNX) overvalued or undervalued?

Currently Beta Bionics, Inc. Common Stock (BBNX) is in undervalued.

News

From:

To:

News
Beta Bionics Announces Agreement with Abbott to Integrate the iLet Bionic Pancreas with Abbott's Future Dual Glucose-Ketone Sensor IRVINE, Calif., June 19, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, announced its intention to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott's future dual glucose-ketone sensor in the U.S. Thu, Jun. 19, 2025
Beta Bionics, Inc. (BBNX) Q1 2025 Earnings Call Transcript Beta Bionics, Inc. (NASDAQ:BBNX ) Q1 2025 Results Conference Call May 6, 2025 4:30 PM ET Company Participants Blake Beber - Head, IR Sean Saint - President and Chief Executive Officer Stephen Feider - Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Mike Kratky - Leerink Partners Matthew Blackman - Stifel Travis Steed - Bank of America Jeffrey Cohen - Ladenburg Thalmann Brooks O'Neil - Lake Street Capital Markets Kelly Close - Close Concerns Operator Good afternoon, and welcome to the Beta Bionics First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. Sat, May. 10, 2025
Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025 IRVINE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2025 and raised its annual guidance for the year ending December 31, 2025. Tue, May. 06, 2025
Beta Bionics to Present at the Bank of America Securities Health Care Conference IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at 12:35 pm Eastern Time (9:35 am Pacific Time). Thu, May. 01, 2025
Beta Bionics: Slowing Down Or Being Conservative? Beta Bionics' iLet product offers a simplified diabetes treatment, but shares have plunged 60% since the IPO due to a non-inspiring 2025 outlook, indicating potential lost market momentum. Despite strong initial growth and a significant IPO, the company's operating losses and competitive risks warrant a cautious investment stance. The 2025 sales guidance of $80-$85 million implies no sequential growth, raising concerns about market competitiveness and potential margin pressure. Thu, Apr. 24, 2025

Transcripts

Transcipts Data
Beta Bionics, Inc. Common Stock (BBNX) on Q1 2025 Results - Earnings Call Transcript SA Transcripts Sat, May. 10, 2025

SEC Filings

SEC Filings
Beta Bionics, Inc. Common Stock (BBNX) - 8-K - Current report SEC Filings 06/23/2025
Beta Bionics, Inc. Common Stock (BBNX) - 4 SEC Filings 06/04/2025
Beta Bionics, Inc. Common Stock (BBNX) - SCHEDULE 13G SEC Filings 05/15/2025
Beta Bionics, Inc. Common Stock (BBNX) - SCHEDULE 13G/A SEC Filings 05/12/2025
Beta Bionics, Inc. Common Stock (BBNX) - SCHEDULE 13G SEC Filings 05/12/2025
Beta Bionics, Inc. Common Stock (BBNX) - 8-K - Current report SEC Filings 05/06/2025
Beta Bionics, Inc. Common Stock (BBNX) - 10-Q - Quarterly Report SEC Filings 05/06/2025
Beta Bionics, Inc. Common Stock (BBNX) - SCHEDULE 13G SEC Filings 05/02/2025
Beta Bionics, Inc. Common Stock (BBNX) - SCHEDULE 13G SEC Filings 04/09/2025
Beta Bionics, Inc. Common Stock (BBNX) - 10-K/A - Current report SEC Filings 03/28/2025
Beta Bionics, Inc. Common Stock (BBNX) - 8-K - Current report SEC Filings 03/27/2025
Beta Bionics, Inc. Common Stock (BBNX) - 4 SEC Filings 03/27/2025
Beta Bionics, Inc. Common Stock (BBNX) - 3 SEC Filings 03/27/2025
Beta Bionics, Inc. Common Stock (BBNX) - 8-K - Current report SEC Filings 03/25/2025
Beta Bionics, Inc. Common Stock (BBNX) - 10-K - Current report SEC Filings 03/25/2025
Beta Bionics, Inc. Common Stock (BBNX) - 4 SEC Filings 03/18/2025
Beta Bionics, Inc. Common Stock (BBNX) - 4 SEC Filings 03/03/2025
Beta Bionics, Inc. Common Stock (BBNX) - SCHEDULE 13G SEC Filings 02/07/2025
Beta Bionics, Inc. Common Stock (BBNX) - SCHEDULE 13G SEC Filings 02/05/2025
Beta Bionics, Inc. Common Stock (BBNX) - S-8 SEC Filings 02/03/2025
Beta Bionics, Inc. Common Stock (BBNX) - 4 SEC Filings 02/03/2025
Beta Bionics, Inc. Common Stock (BBNX) - 8-K - Current report SEC Filings 01/31/2025
Beta Bionics, Inc. Common Stock (BBNX) - 424B4 SEC Filings 01/31/2025
Beta Bionics, Inc. Common Stock (BBNX) - 4 SEC Filings 01/31/2025
Beta Bionics, Inc. Common Stock (BBNX) - EFFECT SEC Filings 01/30/2025
Beta Bionics, Inc. Common Stock (BBNX) - SEC STAFF LETTER SEC Filings 01/29/2025
Beta Bionics, Inc. Common Stock (BBNX) - S-1MEF SEC Filings 01/29/2025
Beta Bionics, Inc. Common Stock (BBNX) - CERT SEC Filings 01/29/2025
Beta Bionics, Inc. Common Stock (BBNX) - 3 SEC Filings 01/29/2025
Beta Bionics, Inc. Common Stock (BBNX) - S-1/A SEC Filings 01/28/2025
Beta Bionics, Inc. Common Stock (BBNX) - CORRESP SEC Filings 01/28/2025
Beta Bionics, Inc. Common Stock (BBNX) - 8-A12B SEC Filings 01/27/2025
Beta Bionics, Inc. Common Stock (BBNX) - S-1/A SEC Filings 01/23/2025
Beta Bionics, Inc. Common Stock (BBNX) - CORRESP SEC Filings 01/23/2025
Beta Bionics, Inc. Common Stock (BBNX) - UPLOAD SEC Filings 01/22/2025
Beta Bionics, Inc. Common Stock (BBNX) - S-1/A SEC Filings 01/22/2025
Beta Bionics, Inc. Common Stock (BBNX) - CORRESP SEC Filings 01/10/2025
Beta Bionics, Inc. Common Stock (BBNX) - S-1 SEC Filings 01/06/2025
Beta Bionics, Inc. Common Stock (BBNX) - CORRESP SEC Filings 01/06/2025
Beta Bionics, Inc. Common Stock (BBNX) - UPLOAD SEC Filings 12/19/2024
Beta Bionics, Inc. Common Stock (BBNX) - DRS/A SEC Filings 12/16/2024
Beta Bionics, Inc. Common Stock (BBNX) - DRSLTR SEC Filings 12/13/2024
Beta Bionics, Inc. Common Stock (BBNX) - UPLOAD SEC Filings 12/06/2024
Beta Bionics, Inc. Common Stock (BBNX) - DRS/A SEC Filings 11/25/2024
Beta Bionics, Inc. Common Stock (BBNX) - DRSLTR SEC Filings 11/22/2024
Beta Bionics, Inc. Common Stock (BBNX) - UPLOAD SEC Filings 11/06/2024
Beta Bionics, Inc. Common Stock (BBNX) - SEC STAFF LETTER SEC Filings 10/31/2024
Beta Bionics, Inc. Common Stock (BBNX) - DRS/A SEC Filings 10/28/2024
Beta Bionics, Inc. Common Stock (BBNX) - DRSLTR SEC Filings 10/25/2024
Beta Bionics, Inc. Common Stock (BBNX) - SEC STAFF LETTER SEC Filings 10/22/2024
Beta Bionics, Inc. Common Stock (BBNX) - UPLOAD SEC Filings 10/10/2024
Beta Bionics, Inc. Common Stock (BBNX) - DRS SEC Filings 09/13/2024
Beta Bionics, Inc. Common Stock (BBNX) - C-AR SEC Filings 04/25/2024
Beta Bionics, Inc. Common Stock (BBNX) - D SEC Filings 09/15/2023
Beta Bionics, Inc. Common Stock (BBNX) - C-AR SEC Filings 04/26/2023
Beta Bionics, Inc. Common Stock (BBNX) - C-AR/A SEC Filings 09/01/2022
Beta Bionics, Inc. Common Stock (BBNX) - C-AR SEC Filings 04/29/2022
Beta Bionics, Inc. Common Stock (BBNX) - D SEC Filings 03/02/2022
Beta Bionics, Inc. Common Stock (BBNX) - C-AR/A SEC Filings 05/14/2021
Beta Bionics, Inc. Common Stock (BBNX) - C-AR SEC Filings 04/30/2021
Beta Bionics, Inc. Common Stock (BBNX) - C-AR/A SEC Filings 05/22/2020
Beta Bionics, Inc. Common Stock (BBNX) - C-AR SEC Filings 04/29/2020
Beta Bionics, Inc. Common Stock (BBNX) - D SEC Filings 07/22/2019
Beta Bionics, Inc. Common Stock (BBNX) - C-AR SEC Filings 04/30/2019
Beta Bionics, Inc. Common Stock (BBNX) - D/A SEC Filings 10/23/2018
Beta Bionics, Inc. Common Stock (BBNX) - D/A SEC Filings 09/17/2018
Beta Bionics, Inc. Common Stock (BBNX) - C-AR SEC Filings 04/30/2018
Beta Bionics, Inc. Common Stock (BBNX) - D SEC Filings 12/27/2017
Beta Bionics, Inc. Common Stock (BBNX) - C-AR SEC Filings 05/01/2017
Beta Bionics, Inc. Common Stock (BBNX) - C-U SEC Filings 09/09/2016
Beta Bionics, Inc. Common Stock (BBNX) - C/A SEC Filings 08/26/2016
Beta Bionics, Inc. Common Stock (BBNX) - C/A SEC Filings 08/23/2016
Beta Bionics, Inc. Common Stock (BBNX) - C SEC Filings 05/16/2016

Press Releases

StockPrice Release
Beta bionics to announce second quarter 2025 financial results on july 29, 2025 07/02/2025
Beta bionics announces agreement with abbott to integrate the ilet bionic pancreas with abbott's future dual glucose-ketone sensor 06/19/2025
Beta bionics reports first quarter 2025 financial results and raises annual guidance for full year 2025 05/06/2025
Beta bionics to present at the bank of america securities health care conference 05/01/2025
Beta bionics to host investor event on june 22, 2025 04/09/2025
Beta bionics announces board appointment of gerard michel 03/27/2025
Beta bionics announces fourth quarter and full year 2024 financial results and introduces annual guidance for full year 2025 03/25/2025
Beta bionics to announce fourth quarter and full year 2024 financial results on march 25, 2025 02/27/2025
Beta bionics announces closing of $234.6 million initial public offering and full exercise of underwriters' option to purchase additional shares 01/31/2025
Beta bionics announces pricing of upsized $204 million initial public offering 01/29/2025

More Headlines

News
Beta Bionics to Host Investor Event on June 22, 2025 IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it will host an investor event on Sunday, June 22, 2025, in conjunction with the 85th Scientific Sessions of the American Diabetes Association (ADA) taking place June 20-23, 2025, in Chicago, IL. The event will begin at 7:00 am Central Time (8:00 am Eastern Time) and conclude at approximately 8:30 am Central Time (9:30 am Eastern Time). 04/09/2025
Beta Bionics Announces Board Appointment of Gerard Michel IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (Nasdaq: DCTH), a commercial-stage interventional oncology company. 03/27/2025
Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025 IRVINE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended December 31, 2024 and introduced its annual guidance for the year ending December 31, 2025. 03/25/2025
Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2024 performance. 02/27/2025
Insider Buying Surges in February, Especially in These 6 Stocks In January, the number of notable insider purchases was somewhat muted. 02/09/2025
Beta Bionics: A Sugar Rush For This IPO Beta Bionics' IPO was highly successful, trading 40% above the offer price due to strong growth prospects and relatively cheap sales multiples. The company's iLet product offers a new, simplified treatment for Type 1 diabetes, with plans to expand to Type 2, doubling the market potential. Despite impressive revenue growth, Beta Bionics faces substantial operating losses, but it has a solid cash position to fund these losses for years. 02/02/2025
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK Technology, and TV Channels Network. Two IPOs are currently scheduled for the week ahead, and a few more sizable names are eligible to launch. 02/01/2025
Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares IRVINE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the closing of its upsized initial public offering of 13,800,000 shares of common stock, including the full exercise of the underwriters' option to purchase 1,800,000 additional shares, consisting of 475,000 additional shares from Beta Bionics and 1,325,000 shares from the selling stockholders named in the prospectus, at a price to the public of $17.00 per share. The gross proceeds to Beta Bionics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Beta Bionics, were approximately $212.1 million. Beta Bionics did not receive any proceeds from any sale of shares by the selling stockholders. The shares began trading on the Nasdaq Global Market on January 30, 2025 under the ticker symbol “BBNX.” 01/31/2025
Beta Bionics Announces Pricing of Upsized $204 Million Initial Public Offering IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common stock at a price to the public of $17.00 per share. The gross proceeds to Beta Bionics from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Beta Bionics, are expected to be $204.0 million. In addition, the underwriters have a 30-day option to purchase up to an additional 1,800,000 shares of common stock at the public offering price, less underwriting discounts and commissions, consisting of 475,000 shares from Beta Bionics and 1,325,000 shares from the selling stockholders named in the prospectus. Beta Bionics will not receive any proceeds from any sale of shares by the selling stockholders. 01/29/2025
U.S. IPO Weekly Recap: Flowco Launches First Major IPO Of 2025 As Smithfield, Others Join The Pipeline Three very small Asian issuers and one blank check company listed in the US this past week, though the biggest headlines came from a sizable launch and notable new filings. Energy equipment and services provider Flowco launched the year's first major IPO, planning to raise $392 million and list in the week ahead. Two IPOs are currently scheduled in the week ahead, although some other small issuers may join the calendar throughout the week. 01/11/2025

Unlock

BBNX Ratings Summary

BBNX Quant Ranking

Is Beta Bionics, Inc. Common Stock (BBNX) a buy, sell, or hold?

What is Beta Bionics, Inc. Common Stock's stock price?

Is Beta Bionics, Inc. Common Stock (BBNX) overvalued or undervalued?

Beta Bionics to Host Investor Event on June 22, 2025

Beta Bionics Announces Board Appointment of Gerard Michel

Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025

Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Insider Buying Surges in February, Especially in These 6 Stocks

Beta Bionics: A Sugar Rush For This IPO

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Beta Bionics Announces Pricing of Upsized $204 Million Initial Public Offering

U.S. IPO Weekly Recap: Flowco Launches First Major IPO Of 2025 As Smithfield, Others Join The Pipeline

Company Details

Ratings

Quant Factor Grades

Trading

Dividend Grades

Dividend

Earnings

Valuation

Growth

Performance

Momentum

Profitability

Risk

Ownership

Debt